<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p92" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_92{left:130px;bottom:1195px;letter-spacing:0.22px;}
#t2_92{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_92{left:238px;bottom:1115px;letter-spacing:-0.01px;}
#t4_92{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t5_92{left:238px;bottom:1076px;letter-spacing:-0.01px;}
#t6_92{left:238px;bottom:1057px;letter-spacing:-0.01px;}
#t7_92{left:238px;bottom:1037px;letter-spacing:-0.01px;}
#t8_92{left:238px;bottom:1018px;letter-spacing:-0.01px;}
#t9_92{left:238px;bottom:964px;letter-spacing:-0.01px;}
#ta_92{left:238px;bottom:944px;letter-spacing:-0.01px;}
#tb_92{left:238px;bottom:925px;letter-spacing:-0.01px;}
#tc_92{left:238px;bottom:906px;letter-spacing:-0.01px;}
#td_92{left:238px;bottom:886px;letter-spacing:-0.01px;}
#te_92{left:238px;bottom:867px;letter-spacing:-0.01px;}
#tf_92{left:238px;bottom:847px;letter-spacing:-0.01px;}
#tg_92{left:238px;bottom:828px;letter-spacing:-0.01px;}
#th_92{left:238px;bottom:808px;letter-spacing:-0.01px;}
#ti_92{left:238px;bottom:789px;letter-spacing:-0.01px;}
#tj_92{left:238px;bottom:770px;letter-spacing:-0.01px;}
#tk_92{left:238px;bottom:677px;letter-spacing:-0.01px;}
#tl_92{left:238px;bottom:657px;letter-spacing:-0.01px;}
#tm_92{left:238px;bottom:638px;letter-spacing:-0.01px;}
#tn_92{left:238px;bottom:618px;letter-spacing:-0.01px;}
#to_92{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_92{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_92{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_92{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts92" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg92Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg92" style="-webkit-user-select: none;"><object width="908" height="1286" data="92/92.svg" type="image/svg+xml" id="pdf92" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_92" class="t s0_92">7.7. Residual tumor, recurrence and recurrent metastasis </span><span id="t2_92" class="t s1_92">92 </span>
<span id="t3_92" class="t s2_92">irradiated area can significantly reduce the risk of fistulas, although there is no evidence </span>
<span id="t4_92" class="t s2_92">regarding the type of tissue transfer [325, 328-331]. From numerous recent reports, we now </span>
<span id="t5_92" class="t s2_92">know that a laryngeal carcinoma that is in principle resectable after primary chemoradiotherapy </span>
<span id="t6_92" class="t s2_92">does not necessarily have to be salvage operable. According to new reports, only less than half </span>
<span id="t7_92" class="t s2_92">of the previously resectable tumors turned out to be no longer resectable/operable after </span>
<span id="t8_92" class="t s2_92">chemoradiotherapy [322]. </span>
<span id="t9_92" class="t s2_92">Repeated radiotherapy or radiochemotherapy is often offered if the recurrence is unresectable </span>
<span id="ta_92" class="t s2_92">and there is no other option for curative treatment. In numerous smaller studies with selected </span>
<span id="tb_92" class="t s2_92">patients, 5-year survival rates of between 9 and 20% and local tumor control rates of 11-48% </span>
<span id="tc_92" class="t s2_92">were described [332-335]. Tumor control was significantly better when the second radiation </span>
<span id="td_92" class="t s2_92">treatment was administered with more than 50 Gy [333-335]. The local side effects on healthy </span>
<span id="te_92" class="t s2_92">tissue are associated with serious late radiation damage in 9-18% [334, 336, 337]. In large case </span>
<span id="tf_92" class="t s2_92">series, fibrosis of the neck muscles, oral mucosal necrosis in 41%, trismus in 30% and fatal </span>
<span id="tg_92" class="t s2_92">complications in 11% were described after a second radiation treatment [332]. Severe acute </span>
<span id="th_92" class="t s2_92">radiation toxicity is more likely in patients over 80 years of age, especially after second </span>
<span id="ti_92" class="t s2_92">irradiation to the neck [337]. There is evidence that IMRT may help improve the therapeutic </span>
<span id="tj_92" class="t s2_92">index of second irradiation [334]. </span>
<span id="tk_92" class="t s2_92">If a lymph node metastasis occurs after therapy or if there is a residual lymph node metastasis, </span>
<span id="tl_92" class="t s2_92">the same therapeutic indications apply as for the primary tumor. When considering </span>
<span id="tm_92" class="t s2_92">resectability, the topographical relationship of the metastasis to the large blood vessels (carotid </span>
<span id="tn_92" class="t s2_92">artery), the skull base and the upper thoracic aperture must be taken into account. </span>
<span id="to_92" class="t s0_92">Â© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
